<DOC>
	<DOCNO>NCT00060671</DOCNO>
	<brief_summary>The purpose study determine whether combine pixantrone ( BBR 2778 , INN name pending ) monoclonal antibody rituximab , lead increase period patient ' remission , compare rituximab alone .</brief_summary>
	<brief_title>Comparative Trial Pixantrone Combination With Rituximab Indolent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>This trial conduct patient indolent ( low-grade ) non-Hodgkin 's lymphoma , either relapsed refractory previous treatment . Pixantrone belong DNA intercalator family chemotherapy agent , include anthracyclines . DNA intercalators commonly use treat patient indolent NHL , often combination monoclonal antibody rituximab . This study represent first large-scale , comparative trial indolent NHL , design determine whether response rate time tumour progression patient treat combination rituximab DNA intercalator , significantly high see patient treated rituximab alone . This trial randomize control , mean participate patient randomly assign one two treatment group : 1 . Patients treat pixantrone rituximab , combination 2 . Patients treat rituximab This trial expect recruit around 800 patient US , Europe Israel , 400 patient recruit group . Patients treat around 18 week recieve regular physician monitoring five year end treatment .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Pixantrone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Inclusion criterion : Patients relapse refractory indolent nonHodgkin 's lymphoma ( NHL ) , include follicular lymphoma grade I II Presenting episode progressive disease , follow 15 prior treatment ( either radiation , chemotherapy rituximab ) . Exclusion criterion : Patients fail respond previous rituximab treatment , relapse within 6 month first rituximab infusion Patients know allergic reaction rituximab murine derive protein .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Pixantrone</keyword>
	<keyword>BBR 2778</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>DNA Intercalator</keyword>
	<keyword>Anthracycline</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Mabthera</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>antibody</keyword>
	<keyword>NHL</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>indolent</keyword>
	<keyword>low grade</keyword>
	<keyword>Novuspharma</keyword>
</DOC>